Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan-Reference-Cited by-同舟云学术

Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan

Published:2012-09-14 Issue:10 Volume:103 Page:1839-1847
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Oki Yasuhiro¹,Kondo Yutaka²,Yamamoto Kazuhito¹,Ogura Michinori³,Kasai Masanobu³,Kobayashi Yukio⁴,Watanabe Takashi⁴,Uike Naokuni⁵,Ohyashiki Kazuma⁶,Okamoto Shin-ichiro⁷,Ohnishi Kazunori⁸,Tomita Akihiro⁹,Miyazaki Yasushi¹⁰,Tohyama Kaoru¹¹,Mukai Harumi Y.¹²,Hotta Tomomitsu¹³,Tomonaga Masao¹⁴

Affiliation:

1. Department of Hematology and Cell Therapy; Aichi Cancer Center Hospital; Nagoya; Japan

2. Division of Molecular Oncology; Aichi Cancer Center Research Institute; Nagoya; Japan

3. Department of Hematology and Oncology; Nagoya Daini Red Cross Hospital; Nagoya; Japan

4. Hematology Division; National Cancer Center Hospital; Tokyo; Japan

5. Department of Hematology; National Hospital Organization Kyushu Cancer Center; Fukuoka; Japan

6. Division of Hematology; Tokyo Medical University Hospital; Tokyo; Japan

7. Division of Hematology; Keio University Hospital; Tokyo; Japan

8. Oncology Center; Hamamatsu University School of Medicine; Hamamatsu; Japan

9. Department of Hematology and Oncology; Nagoya University Graduate School of Medicine; Nagoya; Japan

10. Department of Hematology; Nagasaki University Hospital; Nagasaki; Japan

11. Clinical Pathology and Laboratory Medicine; Kawasaki Medical School Hospital; Kurashiki; Japan

12. Janssen Pharmaceutical K.K; Tokyo; Japan

13. National Hospital Organization Nagoya Medical Center; Nagoya; Japan

14. Japanese Red Cross Nagasaki Genbaku Hospital; Nagasaki; Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2012.02386.x/fullpdf

Reference24 articles.

1. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management;Garcia-Manero;Am J Hematol,2011

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. The fundamental role of epigenetic events in cancer;Jones;Nat Rev Genet,2002

4. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes;Shen;J Clin Oncol,2010

5. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes;Kaminskas;Clin Cancer Res,2005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Thrombocytopenia with Acute Cerebral Infarction: A Case Report and Literature Review;Nigerian Journal of Clinical Practice;2023-07

2. Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial;Cancer Medicine;2023-06-23

3. Epigenetic targeted therapies in hematological malignancies;Epigenetic Cancer Therapy;2023

4. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms;Blood Advances;2022-05-27

5. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?;Blood Advances;2022-05-05